EUVIMEDEUVIMED entdecken
Crossref

FDA-approved fulvestrant-induced CAR phase separation enables precise control of CAR T antitumor function

Yuwei Huang, Qichen Zhang, Kun Wang, Xiaohua Ren, Hao He, Jinjiao Wang, Li Li, Zhichao Tan, Jiayong Liu, Guangya Zhu, Haopeng Wang

Cell Stem Cell · 2026-08 · 33 (8) · 1354-1362.e4

DOI: 10.1016/j.stem.2026.06.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Stem Cell, 2026-08. Verfasst von Yuwei Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; Lingang Laboratory, Shanghai 201203, China. Hauptthemen laut MEDLINE: Fulvestrant, Receptors, Chimeric Antigen, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission, National Natural Science Foundation of China, Shanghai Municipality Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy faces challenges, such as tumor relapse due to antigen loss and poor CAR T cell expansion in vivo. Optimal tonic signaling (spontaneous CAR signaling) is crucial for CAR T cell fitness and antitumor function, requiring precise calibration to avoid dysfunction or exhaustion. Although CAR phase separation can enhance CAR clustering and tonic signaling to improve cytotoxicity and antigen sensitivity, constitutively high signaling could lead to potential side effects, including cytokine storm and neuronal toxicity. To overcome this limitation, we developed a drug-inducible phase-separation CAR (iPhase-CAR) system utilizing FDA-approved fulvestrant and an engineered estrogen receptor α (ERα) mutant as the drug-inducible phase-separation (DiPS) module. Incorporating the DiPS module into CARs enables drug-inducible clustering of CARs on T cell membranes. iPhase-CAR T cells demonstrate superior antitumor function. This system provides quantitative, reversible promotion of CAR T effector functions, enabling precise control over therapeutic efficacy only upon administration of the FDA-approved drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FulvestrantReceptors, Chimeric AntigenT-LymphocytesImmunotherapy, AdoptiveUnited States Food and Drug AdministrationHumansPhase SeparationAnimalsUnited StatesCell Line, TumorSignal Transduction

Stichwörter der Autor:innen

CAR T cell therapyfulvestrantliquid-liquid phase separationtonic signaling

Substanzen

FulvestrantReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; Lingang Laboratory, Shanghai 201203, China.
  • Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; Changping Laboratory, Beijing 102206, China.
  • Changping Laboratory, Beijing 102206, China.
  • Lingang Laboratory, Shanghai 201203, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.

Förderung

  • Shanghai Municipal Health Commission
  • National Natural Science Foundation of China
  • Shanghai Municipality Science and Technology Commission
  • Changping Laboratory
  • National Science Fund for Distinguished Young Scholars
  • Program of Shanghai Academic Research Leader

Zitieren

APA

Huang, Y., Zhang, Q., Wang, K., Ren, X., He, H., Wang, J., Li, L., Tan, Z., Liu, J., Zhu, G., & Wang, H. (2026). FDA-approved fulvestrant-induced CAR phase separation enables precise control of CAR T antitumor function. Cell Stem Cell, 33(8), 1354-1362.e4. https://doi.org/10.1016/j.stem.2026.06.005

Vancouver

Huang Y, Zhang Q, Wang K, Ren X, He H, Wang J, et al. FDA-approved fulvestrant-induced CAR phase separation enables precise control of CAR T antitumor function. Cell Stem Cell. 2026;33(8):1354-1362.e4. doi:10.1016/j.stem.2026.06.005

BibTeX
@article{Huang2026,
  author = {Huang, Yuwei and Zhang, Qichen and Wang, Kun and Ren, Xiaohua and He, Hao and Wang, Jinjiao and Li, Li and Tan, Zhichao and Liu, Jiayong and Zhu, Guangya and Wang, Haopeng},
  title = {FDA-approved fulvestrant-induced CAR phase separation enables precise control of CAR T antitumor function},
  journal = {Cell Stem Cell},
  year = {2026},
  volume = {33},
  number = {8},
  pages = {1354--1362.e4},
  doi = {10.1016/j.stem.2026.06.005}
}
Kostenlos starten →